FindTrial
Sign In

To study the role of Zinc combined with standard treatment for COVID-19

Prospective study to assess therapeutic role of Zinc in COVID-19 patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026340
Enrollment
100
Registered
2020-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Zinc sulphate 100mg: Micronutrient Zinc combined with standard treatment Tab Zinc Sulphate 100 mg OD Control Intervention1: Standard treatment: Standard medications

Sponsors

Ramen Goel
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with COVID-19

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women 2. End stage CKD (chronic kidney disease) 3. Patients with dementia, learning disability, mental health needs 4. Unable to understand the procedures and protocol 5. Deemed unfit for the study according to the investigator

Design outcomes

Primary

MeasureTime frame
Reduction in symptoms Duration of stay, ICU admission, ventilator requirement, complications, dischargeTimepoint: Baseline, day 1, day 5, day 7, day 14 or till discharge—

Secondary

MeasureTime frame
Symptom resolutionTimepoint: 14 days—

Countries

India

Contacts

Public ContactRamen Goel

Wockhardt Hospitals

ramengoel@gmail.com9820170763

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026